ISRCTN72347535 https://doi.org/10.1186/ISRCTN72347535

# HMR code: 26-501

| | | |
|---|---|---|
| **Submission date**<br>10/11/2026 | **Recruitment status**<br>Not yet recruiting | [X] Prospectively registered<br>[_] Protocol<br>[_] Statistical analysis plan<br>[_] Results<br>[_] Individual participant data<br>[X] Record updated in last year |
| **Registration date**<br>18/11/2026 | **Overall study status**<br>Deferred | |
| **Last Edited**<br>18/11/2026 | **Condition category**<br>Other | |

**Plain English summary of protocol**
The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

## Contact information

**Type(s)**
Public, Scientific

**Contact name**
None - ALLInBio, Inc.

**Contact details**
ALLInBio, Inc. 3160 Porter Driver, Suite 200
Palo Alto, CA
United States of America
94304
+1 415-725-6030
clinicaltrials@allinbio.com

**Type(s)**
Principal investigator

**Contact name**
Dr Denisa Wilkes

**ORCID ID**
https://orcid.org/0009-0007-3133-5152

**Contact details**
Hammersmith Medicines Research (HMR), 44 Cumberland Avenue, Park Royal
London
United Kingdom
NW10 7EW

+44 (0)20 8961 4130
rec@hmrlondon.com

# Additional identifiers

### Integrated Research Application System (IRAS)
1014425

# Study information

### Scientific Title
HMR code: 26-501
Full scientific title to be added on or before the deferral expiry date

### Study objectives
The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Ethics approval required
Ethics approval required

### Ethics approval(s)
Submitted 21/09/2026, London – Brent Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8129; brent.rec@hra.nhs.uk), ref: 26/LO/0478

### Primary study design
Interventional

### Allocation
Randomized controlled trial

### Masking
Blinded (masking used)

### Control
Placebo

### Assignment
The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Purpose
Phase I trial in healthy participants

### Study type(s)

### Health condition(s) or problem(s) studied
The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Interventions
The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Intervention Type
Drug

### Phase
Phase I

### Drug/device/biological/vaccine name(s)
The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Primary outcome(s)
1. [Outcome] measured using [measure] at [timepoints]. The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Key secondary outcome(s)
The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Completion date
02/06/2028

## Eligibility

### Key inclusion criteria
The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Healthy volunteers allowed
Yes

### Age group
Mixed

### Lower age limit
18 Years

### Upper age limit
80 Years

### Sex
All

### Total final enrolment
0

### Key exclusion criteria

The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.

**Date of first enrolment**
30/11/2026

**Date of final enrolment**
16/08/2027

# Locations

**Countries of recruitment**
United Kingdom

England

**Study participating centre**
**Hammersmith Medicines Research (HMR)**
Hammersmith Medicines Research (HMR), 44 Cumberland Avenue, Park Royal
London
England
NW10 7EW

# Sponsor information

**Organisation**
ALLInBio, Inc.

# Funder(s)

**Funder type**

**Funder Name**
ALLInBio, Inc.

# Results and Publications

**Individual participant data (IPD) sharing plan**

## IPD sharing plan summary

Not expected to be made available